Special Issue

Inflammatory Cytokines as New Therapeutic Targets

Message from the Guest Editors

It is generally known that inflammatory responses are accompanied by the regulation of autoimmune diseases, infectious diseases, and cancers by the immune system. In this process, excessive production of inflammatory cytokine by inflammatory immune cells that mediate inflammatory reactions is known to make the disease get worse. Therefore, research regarding immunomodulating molecules, including monoclonal antibodies and small chemical compounds, is needed to regulate the production and function of inflammatory cytokines in this regard. In this Special Issue, we will deal with research on the regulation of inflammatory immune cells and various kinds of inflammatory cytokines produced by these cells. Reviews and original papers discussing these points are welcome.

Guest Editors

Prof. Dr. Jae Seung Kang

Department of Anatomy and Cell Biology, Institute of Allergy and Clinical Immunology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

Prof. Dr. Yejin Kim

Laboratory of Vitamin C and Antioxidant Immunology, Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

Deadline for manuscript submissions

closed (30 April 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/159583

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

